Connect Biopharma Advances Rademikibart Toward Phase 3
SAN DIEGO, Calif. — September 15, 2026 Connect Biopharma Holdings Limited announced positive preliminary topline results from the global...
IL-4
Advertisement
Turn Therapeutics Reports GX-03 Skin Inflammation Research
Westlake Village, California, August 20, 2026 Turn Therapeutics announced new peer-reviewed research providing in-vivo evidence that GX-03 selectively reduces...
Medicenna Advances MDNA11 and Bizaxofusp Clinical Programs
TORONTO and HOUSTON, August 14, 2026 Medicenna Therapeutics Corp. reported its first-quarter fiscal 2027 financial results and provided a...
Dianthus Unveils DNTH312 Dual-Target Autoimmune Therapy
NEW YORK and WALTHAM, Mass., August 4, 2026 Dianthus Therapeutics, Inc. announced the launch of DNTH312, an internally developed...
Nurix and Sanofi Advance Oral STAT6 Degrader into Phase 1 Clinical Development
BRISBANE, Calif., August 4, 2026 Nurix Therapeutics, Inc. announced it has earned a $10 million development milestone payment after...
Advertisements
Dupixent Approved in Japan for Rare Skin Disease
PARIS, FRANCE & TARRYTOWN, NEW YORK, USA | March 24, 2026 Sanofi and Regeneron have announced that Japan’s Ministry...
Advertisement
